Clinical trials: Myelodysplastic Neoplasm
Myelodysplastic Syndrome
Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003
Multi-center, survival data collection in subjects previously enrolled in study NCT00065156 (Celgene Protocol CC-5013-MDS-003).
- Trial name
- NCT01099267
- Where
- 15 sites in United States, Germany
- Volunteers
- 54 people
- Sponsor
- Celgene
Leukemia
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
RATIONALE: Giving chemotherapy drugs, such as cytarabine and mitoxantrone, before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Trial name
- NCT00609739
- Testing
- cyclosporine, cytarabine, filgrastim
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS.
- Trial name
- AML (NCT02576301)
- Testing
- Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Mateon Therapeutics
Anemia, Leukemia
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
RATIONALE: Thalidomide may stop or slow the growth of cancer cells. Epoetin alfa may stimulate red blood cell production. Combining thalidomide with epoetin alfa may improve anemia, decrease the need for blood transfusions, and…
- Conditions
- Anemia, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00053001
- Testing
- epoetin alfa, thalidomide
- Where
- 2 sites in United States
- Sponsor
- Fallon Clinic
Chronic Myeloproliferative Disorders, Leukemia
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00716911
- Testing
- ganciclovir, polymerase chain reaction, flow cytometry
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Adult, Myelodysplastic Syndromes
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
RATIONALE: Gathering information about quality of life, fatigue, and other symptoms from patients with myelodysplastic syndromes may help doctors learn more about the disease and may help plan treatment.
- Trial name
- PROMYS (NCT00809575)
- Testing
- questionnaire administration, fatigue assessment and management, observation
- Where
- 53 sites in United States, Austria and 10 more
- Volunteers
- 927 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Myelodysplastic Syndromes
Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
The purpose of this study is to determine the safety and efficacy of TLK199 in patients with myelodysplastic syndrome (MDS).
- Trial name
- NCT00035867
- Testing
- TLK199 HCl Liposomes for Injection
- Where
- 9 sites in United States
- Volunteers
- 65 people
- Sponsor
- Telik
Myelodysplastic Syndromes
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
The purpose of this study is to determine whether patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine have improved survival compared to conventional care treatments.
- Trial name
- NCT00071799
- Testing
- Azacitidine, Physician Choice
- Where
- 108 sites in United States, Australia and 13 more
- Volunteers
- 358 people
- Sponsor
- Celgene
Myelodysplastic Syndrome, Anemia in Myelodysplastic Syndromes
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
This research is being conducted to asses if HT-6184 is effective in the treatment of Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia.
- Trial name
- NCT07052006
- Testing
- HT-6184
- Where
- 10 sites in India
- Volunteers
- 37 people
- Sponsor
- Halia Therapeutics, Inc.
Paroxysmal Nocturnal Hemoglobinuria
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
This was a Phase II randomized, open-label, multicenter, efficacy, safety, pharmacokinetic and pharmacodynamic study assessing four iptacopan doses in adult Paroxysmal nocturnal hemoglobinuria (PNH) patients with active hemolysis…
- Trial name
- NCT03896152
- Testing
- LNP023
- Where
- 5 sites in Malaysia, Singapore and 2 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelodysplastic Syndromes
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00104806
- Testing
- cholecalciferol, arsenic trioxide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential
CHIP in Health and Disease
Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic…
- Conditions
- Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential, Clonal Cytopenia of Undetermined Significance (CCUS), Myelodysplastic Syndrome
- Trial name
- CHIP2 (NCT07780552)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
Leukemia, Lymphoma
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
RATIONALE: Giving total-body irradiation and chemotherapy, such as cyclophosphamide, before a donor stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells and helps stop the growth of…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00317785
- Testing
- cyclophosphamide, cyclosporine, methotrexate
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS
Indication:Relapsed or refractory AML in patients for whom no established treatment options are available (this indication will heretofore be referred to as the protocol AML indication), or adult patients with MDS who are…
- Trial name
- NCT04743115
- Testing
- BS HH 002.SA
- Volunteers
- 66 people
- Sponsor
- Shanghai Bensen Pharmaceutical Co., Ltd.
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological…
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Trial name
- NCT05086315
- Testing
- SAR443579
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Sanofi
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
The purpose of this prospective, open-label, single-center study is to evaluate the efficacy and safety of VEN-AZA (venetoclax and azacytidine) followed by modified BUCY (busulfan and cyclophosphamide) as conditioning regimen for…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05823714
- Testing
- VEN+AZA+Modified BUCY
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will receive lymphodepleting chemotherapy (Flu/Cy) and two infusions of cytokine-induced memory-like NK cells at the previously…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04893915
- Testing
- Cytokine-induced memory-like NK cells, Fludarabine, Cyclophosphamide
- Sponsor
- Washington University School of Medicine
Leukemia, Hodgkin Lymphoma
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
The goals of the study are (Phase I) to determine the appropriate dose for Clofarabine with Busulfan as a full-intensity conditioning (Clo/BU4 regimen) prior to transplant and then (Phase II) to investigate the safety and…
- Conditions
- Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT00556452
- Testing
- Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Michigan Rogel Cancer Center
GATA2 Deficiency
Natural History Study of GATA2 Deficiency and Related Disorders
Background: GATA2 deficiency is a genetic disorder that can cause problems with a person s immune system and other body systems. Some people who have this disorder develop few problems from it.
- Trial name
- NCT01905826
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase I trial to study the effectiveness of SB-715992 in treating patients who have acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes.
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00098826
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.